Clinical Trials | The POWER II Trial: Seeking women ages 65 years or older with early-stage, estrogen receptor positive (ER+) breast cancer.

The POWER II trial is trying to see the effects of starting breast cancer medication called endocrine therapy (pre-ET) before breast cancer surgery in older women with early-stage ER+ breast cancer. The POWER II study aims to create individualized treatment plans for patients. The purpose is to see if patients who take pre-ET are less likely to receive too much or too little treatment. Participants will be randomly assigned to one of two groups: • Group 1: 90 days of pre-ET before breast cancer surgery • Group 2: Breast cancer surgery without pre-ET After surgery, all participants will decide with their doctors about whether to receive radiation and/or endocrine therapy. Before and after surgery, participants in both groups will fill out surveys that ask questions about how they tolerate medications and their feelings about their medical care choices. Participants in Group 1 may have 1-2 extra clinic visits. They will also have 1 planned phone call during pre-ET. Participants in both groups will be followed for 2 years after surgery. All study related treatments are standard of care. Participants and/or their insurance company will be billed for medication, tests, and procedures that take place throughout the study. Participants will choose if they would like any leftover tumor tissue that is collected for clinical care (such as at surgery) to be used for additional research purposes. More information can be found here: Clinicaltrials.gov Please contact [email protected] for any questions about the study.